Situation: GLP-1 Receptor Agonists and Alcohol Craving
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes and, under the brand name Wegovy, for chronic weight management. The FDA approval status for alcohol use disorder is absent. Off-label use of semaglutide for alcohol craving has been reported in clinical anecdotes and small case series, but no FDA guidance supports this indication.
Researchers have observed reduced alcohol intake in patients taking GLP-1 agonists for diabetes or obesity. A 2021 study in JCI Insight by Klausen and colleagues found that exenatide, a related GLP-1 agonist, reduced alcohol consumption in patients with alcohol use disorder and obesity. This is a 2 of 3 on evidence quality because it was a randomized controlled trial but with a small sample size.
Semaglutide specifically has been studied in rodent models. A 2022 paper in JCI Insight by Aranäs and colleagues showed that semaglutide reduced alcohol drinking in rats. The mechanism likely involves GLP-1 receptors in brain regions that regulate reward and satiety. Human data for semaglutide and alcohol craving are limited to case reports and ongoing trials.
Regulatory status matters. The FDA has not approved semaglutide for alcohol use disorder. Off-label prescribing is legal but carries different liability and evidence standards. The Federal Register does not list semaglutide as a treatment for alcohol dependence.
Approach: AOD-9604 and Metabolic Enhancement
AOD-9604 is a peptide fragment of human growth hormone (hGH), specifically amino acids 177-191. It is not FDA approved for any indication. The FDA has issued warning letters to companies selling AOD-9604 as a dietary supplement or drug. AOD-9604 is often discussed as a research compound for fat loss and metabolic benefits.
Some researchers hypothesize that AOD-9604 could enhance the metabolic effects of GLP-1 agonists like semaglutide. A 2019 trial in Obesity Research & Clinical Practice by Stier and colleagues tested AOD-9604 for weight loss in obese adults. The trial found no significant difference in weight loss compared to placebo. This is a 1 of 3 on evidence quality because the primary endpoint was not met and the study was small.
Other peptides are also studied in combination with semaglutide. CJC-1295 and tesamorelin are growth hormone-releasing hormone analogs. Retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors. Hexarelin is a growth hormone secretagogue. None of these are FDA approved for weight loss, except tesamorelin for HIV-related lipodystrophy.
For alcohol craving specifically, the interaction between AOD-9604 and GLP-1 pathways is unclear. AOD-9604 does not act on GLP-1 receptors. Its proposed mechanism is lipolysis and inhibition of lipogenesis. There is no published research on AOD-9604 and alcohol consumption.
Outcome: What the Evidence Shows and What Is Missing
Semaglutide shows promise for reducing alcohol craving based on preclinical and early clinical data. The 2022 Aranäs study is a 2 of 3 on evidence quality. The 2021 Klausen study is also a 2 of 3. Both support further research but do not establish clinical efficacy for alcohol use disorder.
AOD-9604 does not have credible evidence for enhancing metabolic benefits when combined with semaglutide. The 2019 Stier trial is a 1 of 3 on evidence quality. No peer-reviewed studies have examined AOD-9604 and semaglutide together for alcohol or metabolic outcomes.
What is missing: randomized controlled trials in humans with alcohol use disorder, long-term safety data for combination therapy, and FDA guidance on off-label use. The FDA has not issued any guidance on semaglutide for alcohol craving. The Federal Register contains no rulemaking on this combination.
Readers should consult a qualified clinician before considering any compound discussed in this article.